Zonisamide sodium

Synonyms: 唑尼沙胺钠; AD 810 sodium; CI 912 sodium
Zonisamide (AD 810) sodium 是一种口服有效的碳酸酐酶 (carbonic anhydrase) 抑制剂,对人类线粒体同工酶 hCA II 和 hCA V 的 Ki 值分别为 35.2 nM 和 20.6 nM,可通过抗细胞凋亡和上调 MnSOD 水平发挥神经保护作用,还能通过增加 Hrd1 的表达改善 AAC 大鼠的心脏功能,可用于癫痫、帕金森和心脏肥大的研究。
产品编号: MS-L09332 CAS No.: 68291-98-5 分子式: C8H7N2NaO3S 分子量: 234.21
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Zonisamide (AD 810) sodium 是一种口服有效的碳酸酐酶 (carbonic anhydrase) 抑制剂,对人类线粒体同工酶 hCA II 和 hCA V 的 Ki 值分别为 35.2 nM 和 20.6 nM,可通过抗细胞凋亡和上调 MnSOD 水平发挥神经保护作用,还能通过增加 Hrd1 的表达改善 AAC 大鼠的心脏功能,可用于癫痫、帕金森和心脏肥大的研究。

生物实验数据

生物活性 Zonisamide (AD 810) sodium is an orally active carbonic anhydrase inhibitor with Ki values of 35.2 nM and 20.6 nM for the human mitochondrial isoenzymes hCA II and hCA V, respectively, exerts neuroprotective effects by inhibiting apoptosis and upregulating MnSOD levels, improves cardiac function in AAC rats by increasing Hrd1 expression, and can be used for research on epilepsy, Parkinson's disease, and cardiac hypertrophy.
IC50 & Target CA V (human):20.6 nM (Ki), CA II (human):35.2μM (Ki)
体外研究
(In Vitro)

Zonisamide sodium (10, 50, 100, 200 µM; 24 h) increases viability of SH-SY5Y cells via an anti-apoptotic effect.
Zonisamide sodium (100 µM; 24 h) shows neuroprotective effects in PD-cellular models. (PD: parkinson’s disease).
Zonisamide sodium (100 µM; 24 h) reduces levels of proapoptotic molecules, and upregulates levels of MnSOD (MnSOD over-expression attenuates MPTP toxicity and protects cells from apoptosis).
Zonisamide sodium (0.1, 0.3, 1 μM; 24 h) inhibits cardiac hypertrophy and fibrosis in vitro.
Zonisamide sodium markedly increases the expression of Hrd1 in Ang II-treated NRCMs.

Cell Viability Assay

Cell Line: SH-SY5Y cells
Concentration: 10, 50, 100, 200 µM
Incubation Time: 24 h
Result: Induced an increase of cell viability, and with the greatest effect being at 100 µM.
Exhibited neuroprotective effect on SH-SY5Y cells (PD-cellular models) when at 100 µM.

Apoptosis Analysis

Cell Line: SH-SY5Y cells
Concentration: 100 µM
Incubation Time: 24 h
Result: Showed an effect of anti-apoptotic.

RT-PCR

Cell Line: NRCMs and cardiac fibroblasts (expose to Ang II for cardiomyocyte hypertrophy and fibrosis model)
Concentration: 0.1, 0.3, 1 μM
Incubation Time: 24 h
Result: Decreased the expression of atrial natriuretic factor (ANF) and cardiomyosin heavy chain β (β-MHC) but increased the expression of cardiac myosin heavy chain α (α-MHC) in NRCMs.
Decreased cardiac expression of the fibrosis-related gene Collagen 1A1 (Col1A1) in cardiac fibroblasts.

Western Blot Analysis

Cell Line: SH-SY5Y cells
Concentration: 100 µM
Incubation Time: 24 h
Result: Reduced the proapoptotic molecules levels of cleaved caspase-9, -3, and p-JNK, and blocked the activation of proapoptotic molecules in SH-SY5Y cells.
Induced an increase in MnSOD levels.(MnSOD over-expression attenuates MPTP toxicity and protects cells from apoptosis).
体内研究
(In Vivo)

Zonisamide sodium (40 mg/kg; i.p.; single daily for 14 days) prevents seizures in FeCl3-induced chronic amygdalar seizures model.
Zonisamide sodium (14, 28, 56 mg/kg; i.p.; single daily for 6 weeks) alleviates cardiac hypertrophy and improved cardiac function in rats subjected to AAC (abdominal aortic constriction).
Zonisamide sodium (14, 28, 56 mg/kg; i.p.; single daily for 6 weeks) upregulates Hrd1 expression and accelerates ERAD in the hearts of AAC rats.

Animal Model: Male Wistar rats (200-250 g; FeCl3-induced chronic amygdalar seizures).
Dosage: 40 mg/kg
Administration: Intraperitoneal injection; single daily for 14 days.
Result: Showed activity of anti-seizures.
Significantly down-regulated GABA transporters GAT-1 in the hippocampus.
Animal Model: Adult male Sprague-Dawley rats (100-120 g; cardiac hypertrophy model).
Dosage: 14, 28, 56 mg/kg (dissolved in 1% DMSO)
Administration: Intraperitoneal injection; single daily for 6 weeks.
Result: Significantly attenuated cardiac hypertrophy and fibrosis.
Increased LV ejection fraction (EF), fractional shortening (FS) and E/A ratio.
Markedly increased the expression of Hrd1 in the hearts of AAC rats.

化学信息

分子量 234.21
分子式 C8H7N2NaO3S
CAS No. 68291-98-5
别名 唑尼沙胺钠; AD 810 sodium; CI 912 sodium

储存&溶解度

溶解度信息
DMSO: Soluble
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础